TexasRelating to patient access to prescription drugs for off-label use for COVID-19 treatment.
What it does
Plain-language analysis is being updated.
Use the official record and source text while enrichment finishes.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2025
- Apr 22Referred to Public HealthLatest
- Apr 22Read first timeMinor
- Apr 14Received from the SenateMinor
- Apr 10Reported engrossed
- Vote recorded passage. Result: pass.Upper
- Apr 10Record vote
- Apr 10PassedPassed Senate
- Apr 10Read 3rd timeMinor
- Apr 10Record vote
- Apr 10Rules suspended-Regular order of business
- Apr 10Record vote
- Apr 10Read 2nd time & passed to engrossmentMinor
- Apr 10Record vote
- Apr 10Rules suspended-Regular order of business
- Apr 10Co-author authorized
- Apr 9Placed on intent calendar
- Apr 7Committee report printed and distributed
- Apr 7Reported favorably w/o amendmentsMinor
- Apr 2Vote taken in committee
- Apr 2Considered in public hearing
- Apr 1Left pending in committee
- Apr 1Testimony taken in committee
- Apr 1Considered in public hearing
- Apr 1Scheduled for public hearing on . . .
- Mar 20Co-author authorized
- Feb 13Referred to Health & Human ServicesMinor
- Feb 13Read first timeMinor
- Jan 23FiledMinor
- Jan 23Received by the Secretary of the SenateIntroduced